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Abstract: Since 1990, when our laboratory published the association of the DRD2 Taq A1 allele and
severe alcoholism in JAMA, there has been an explosion of genetic candidate association studies,
including GWAS. To develop an accurate test to help identify those at risk for at least Alcohol Use
Disorder (AUD), Blum’s group developed the Genetic Addiction Risk Severity (GARS) test, consisting
of ten genes and eleven associated risk alleles. In order to statistically validate the selection of these
risk alleles measured by GARS, we applied strict analysis to studies that investigated the association
of each polymorphism with AUD or AUD-related conditions published from 1990 until 2021. This
analysis calculated the Hardy–Weinberg Equilibrium of each polymorphism in cases and controls.
If available, the Pearson’s χ2 test or Fisher’s exact test was applied to comparisons of the gender,
genotype, and allele distribution. The statistical analyses found the OR, 95% CI for OR, and a post-risk
for 8% estimation of the population’s alcoholism prevalence revealed a significant detection. The
OR results showed significance for DRD2, DRD3, DRD4, DAT1, COMT, OPRM1, and 5HTT at 5%.
While most of the research related to GARS is derived from our laboratory, we are encouraging more
independent research to confirm our findings.
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1. Introduction
Substance Use Disorder (SUD) clinicians and scientists face great obstacles in the
fight against the current Alcohol Use Disorder (AUD) and opioid pandemic worldwide.
Although significant progress has been made, the death toll from narcotic overdoses reached
72,000 fatalities in the United States alone in 2017. The National Institute on Alcohol Abuse
and Alcoholism (NIAAA) and the National Institute on Drug Abuse (NIDA) have not
been able to adequately address the severity of the current substance abuse epidemic using
novel Food and Drug Administration (FDA) approved treatments. Medication-Assisted
Treatments (MAT) that have been approved by the FDA primarily work by modulating the
function of the nucleus accumbens. This is accomplished by inhibiting dopamine release
and function at the pre-neuron of the nucleus accumbens [1,2]. Despite the success of MAT
in reducing overdose deaths, costs, and health care events, a long-term strategy to return
MAT patients to premorbid functioning is necessary. Unfortunately, MAT fail routinely [3],
and upon discontinuation, the rate of overdose and relapse among treated patients mirrors
that of untreated patients. In addition, MAT may induce persistent neurological changes
that compromise endorphin, dopamine, and multiple brain systems. While the chronic
use of agonist therapies may be necessary in the absence of other options, we caution that
data on chronic vs. acute use harm reduction is lacking [4,5]. However, there is evidence
that the long-term use of agonist treatments themselves, such as those used for Opioid Use
Disorder (OUD), may in fact precipitate Reward Deficiency Syndrome (RDS) [5], and result
in all the negative sequalae associated with it.
Drug overdoses are the most prevalent in the United States, but they are an international problem that demands urgent, innovative solutions. Short-term opioid substitution
therapy can reduce harm; however, long-term patients risk being locked into a lifetime of
SUD [5]. Alternatively, inducing “psychological extinction” by weakening a conditioned
response over time using the narcotic antagonist, naltrexone, blocks delta and mu opioid receptors [6]. However, one difficulty encountered when using narcotic antagonism
is compliance, which is moderated by the individual’s genetic antecedents [7]. Other
FDA-approved treatments for alcoholism function through the inhibition of dopaminergic
signaling [8,9].
There is increasing movement to opt for the non-addicting narcotic antagonist naltrexone to treat AUD. Recent studies have shown that naltrexone is beneficial by attenuating
craving via “psychological extinction” and reducing relapse. Buprenorphine is currently
the MAT of choice, but injectable naltrexone plus an agent to improve dopaminergic function and tone may renew interest amongst addiction physicians and patients. Even with
the extended injectable option, there is still poor compliance. As such, our group described
an open-label investigation in humans showing improvement in naltrexone compliance
and outcomes with dopamine augmentation with the pro-dopamine regulator KB220
(262 days) compared to naltrexone alone (37 days) [6]. This well-studied complex consists
of amino-acid neurotransmitter precursors and enkephalinase inhibitor therapy compared
to standard treatment. Consideration of this novel paradigm shift may assist in addressing
the current opioid and alcohol epidemics and the broader question of reward deficiency
in general.
Blum’s group first coined the term “RDS” in 1995 to identify a group of behaviors with
a common neurobiological mechanism associated with a polymorphic allelic propensity for
hypodopaminergia as determined by measuring a number of reward genes and associated
risk alleles. Understanding this, coupled with the rising scientific consensus regarding
the underlying concept of RDS, supports the hypothesis of a common mechanism that
groups both chemical and behavioral addictions together [10]. The disruption of neuro-
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modulation and its negative impact on neurotransmission resulting from chronic exposure
to drugs and behavioral addictions requires an approach that involves attaining “dopamine
homeostasis,” especially for AUD [11].
Subsequent large-scale genomics studies have had limited success in identifying alleles
implicated in addiction and RDS. Despite the utility of Genome-Wide Association Studies
(GWAS) and next-generation sequencing, some key issues exist. For example, GWAS is a
useful tool for identifying new clusters of genes that may contribute to genetic antecedents
related to specific RDS behaviors such as AUD. The next key step following the GWAS
results is to converge the data to identify individual candidate genes. Thus, if there is
indeed a blueprint or clue regarding specific known genes and associated polymorphic
risk alleles linked to a specific phenotype such as AUD, it is significant even though the
contribution of each gene may be small.
Several neurotransmitters are involved in the processing of reward and punishment.
These pathways involve at least six quintessential neurotransmitters and many second
messengers linked to the mesolimbic and Pre-Frontal Cortex (PFC). One function is to
regulate the final pathway of “wanting”, causing net neuronal dopamine release. Figure 1
provides a schematic representation of the Brain Reward Cascade (BRC), showing the
interaction of serotonergic, cannabinoidergic, opioidergic, GABAergic, glutaminergic, and
dopaminergic systems related to net dopamine release at the Nucleus Accumbens (NAc).
In this article, the authors highlight dopamine based on the understanding that the healthy
processing of an initial action potential in the brain requires the integrity of the entire
neurotransmitter complex of the brain reward circuitry. The cascading interactions result in
the balanced release of dopamine at the NAc and across many brain regions. These regions
are involved in cognition (memory), motivation, stress reduction, decision-making, recall,
pleasure, cravings, drug reinstatement, and well-being.

Figure 1. Illustrates the interaction of at least six major neurotransmitter pathways involved in the
Brain Reward Cascade (BRC). In the hypothalamus, environmental stimulation causes the release of
serotonin, which in turn, via 5HT-2a receptors, activates (the green, equal sign) the subsequent release
of opioid peptides into the hypothalamus. Then, the opioid peptides have two distinct effects, possibly
via two different opioid receptors. (A) Inhibits (the red hash sign) through the Mu-opioid receptor
(possibly via enkephalin) and projects to the substania nigra to GABAA neurons. (B) Stimulates
(the green, equal sign) cannabinoid neurons (e.g., anandamide and 2-archydonoglcerol) through
beta–endorphin-linked delta receptors, which in turn inhibit GABAA neurons at the substania nigra.
Cannabinoids, primarily 2-archydonoglcerol, when activated, can also indirectly disinhibit (the red
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hash sign) GABAA neurons in the substania nigra through activation of G1/0 coupled to CB1
receptors. Similarly, glutamate neurons located in the Dorsal Raphe Nuclei (DRN) can indirectly
disinhibit GABAA neurons in the substania nigra by activating GLU M3 receptors (the red hash
sign). GABAA neurons, when stimulated, will, in turn, powerfully (the red hash signs) inhibit
Ventral Tegmental Area (VTA) glutaminergic drive via GABAB 3 neurons. Finally, glutamate neurons
in the VTA will project to dopamine neurons through NMDA receptors (the green, equal sign) to
preferentially release dopamine at the NAc, shown as a bullseye indicating well-being (Blum et al.
with permission).

In keeping with the current literature, we are cognizant of the many second messengers as well as the interrelatedness of at least seven finite neurotransmitter systems
involving dopaminergic activity. We are not proposing that these genes are unimportant;
rather, that they influence the final dopaminergic pathway and its function at the nucleus
accumbens. We make this distinction to avoid confusion and to inform the readership
that hypodopaminergia is, in fact, a significant factor that influences unwanted substance
and non-substance addictive behavior seeking. In this regard, being cognizant of these
difficulties and awaiting further research, the BRC was utilized as a blueprint (Figure 1) for
a literature review to determine each allele associated with a hypodopaminergic polymorphism. These alleles were proposed for a GARS panel in case–control studies, specifically
for alcoholism (Table 1).
Table 1. Gene polymorphisms under consideration and the literature summary.
Gene/Polymorphism

Dopamine D1 Receptor (DRD1):
rs4532—risk allele G

Dopamine D2 Receptor (DRD2):
rs1800497—risk allele A1

Dopamine D3 Receptor (DRD3):
rs6280—risk allele C (Ser9Gly)

Dopamine D4 Receptor (DRD4):
rs1800955—risk allele C (48bp
repeat VNTR)

Dopamine Transporter Receptor
(DAT1): SLC6A3 30 -UTR—risk
allele A9 (40bp repeat VNTR)

Number of
Reference Sources

95% CI
Overall Summary

3

The genetic variation in DRD1 and its relationship to a predisposition to
alcoholism have been supported by various studies. A statistically
significant association of DRD1 rs4532 polymorphism with alcohol
dependence was found among Indian males (90 cases vs. 122 controls).
Other studies also demonstrated that this could be associated with the
impulsivity and aggressiveness of AUD patients.

118

From the meta-analysis of numerous case–control studies (total of 18,290
cases vs. 19,809 controls, including US Caucasian, native and
African-American, British, French, Italian, Swedish, Finnish, Spanish,
Mexican, Brazilian, Scandinavian, Japanese) pooled with the random
effect models, the DRD2 rs1800497 was found to be associated with a risk
of AUD and several AUD-related conditions.

3

Several case–control studies investigated the association between the
DRD3 rs6280 polymorphism and alcohol dependence. In a Korean study
(243 cases vs. 130 controls), the DRD3 rs6280 polymorphism was
significantly associated with AUD development.

35

A meta-analysis of various case–control studies (total 2997 cases vs. 2588
controls, including US Caucasian, Mexican-American, Indian) pooled
with the random effect models found that the DRD4 rs1800955
polymorphism was associated with the risk of developing AUD and
AUD-related conditions.

43

The central dopaminergic reward pathway is likely involved in alcohol
intake and the progression of alcohol dependence. DAT1 is a primary
mediator of dopaminergic neurotransmission. From the meta-analysis of
numerous case–control studies (total 3790 cases vs. 3446 controls) pooled
with the random effect models, the DAT1 SLC6A3 30 -UTR risk allele was
found to be marginally associated with a risk of AUD
and/AUD-related conditions.
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Table 1. Cont.
Gene/Polymorphism

Catechol-O-Methyltransferase
(COMT): rs4680—risk allele G
(Val158Met)

µ-Opioid Receptor (OPRM1):
rs1799971—risk allele G
(A118G)

γ-Aminobutyric Acid (GABA)
A Receptor, β-3 Subunit
(GABRB3): CA repeat—risk
allele 181

Monoamine Oxidase A
(MAO-A): 30 30bp VNTR -risk
allele 4R DNRP

Serotonin Transporter Receptor
(5HTT) Linked Promoter Region
(5HTTLPR) in SLC6A4:
rs25531—risk allele S0

Number of
Reference Sources

95% CI
Overall Summary

13

A plethora of evidence supports COMT as a candidate gene that likely
contributes to schizophrenia and substance use disorder. A meta-analysis
of several case–control studies (total of 1212 cases vs. 933 controls,
including US Caucasian, Finnish, Croatian, and Taiwanese) pooled with
a random effect model, the association of COMPT rs4680 polymorphism
with the risk of AUD and AUD-related conditions was found to have
marginal statistical significance.

28

Opioid receptors play an essential role in ethanol reinforcement and
alcohol dependence risk. Some features of alcohol dependence are likely
associated with polymorphisms of the OPRM1 gene expressing µ-opioid
receptors. From the meta-analysis of case–control studies (total of 3096
cases vs. 2896 controls, including US Caucasian, Spanish, Turkish, and
Asian) pooled with the random effect model, the results indicated that
the association of a functional OPRM variant and the risk of alcohol
dependence was found to have marginal statistical significance.

6

The GABAergic system has been implicated in alcohol-related behaviors.
From case–control studies (171 cases vs. 45 controls), the association of
variants of the GABRB3 gene with alcohol dependence is, however,
inconclusive. A more extensive controlled study is required for
improved results.

6

The function of monoamine oxidase (MAO) in alcoholism was
determined using several case–control studies (170 cases vs. 177 controls).
Although genetic heterogeneity is suspected of underlying alcoholism
and MAO-A mutations may play a role in susceptibility to alcoholism,
the overall results were not found to be statistically significant. A more
extensive controlled study is required to obtain conclusive results.

20

Serotonin (5-HT) has been demonstrated to regulate alcohol
consumption. Since the activity of the 5-HT transporter protein (5-HTT)
regulates 5-HT levels, it may contribute to the risk of alcohol dependence.
From the meta-analysis of some case–control studies (total 9996 cases vs.
9950 controls) pooled with the random effect models, the association
between alcohol dependence and a polymorphism in the 5-HTTLPR
was significant.

Blum’s laboratory worked toward developing an accurate genetic test to predict the
liability risk for RDS behaviors, including AUD [12,13]. Geneus Health LLC scientists, in
conjunction with their Genomic Testing Centre, successfully developed the first Genetic
Addiction Risk Severity (GARS) test. The actual association to determine risk using a
clinical outcome, the Addiction Severity Index Media Version (ASI-MV), was accomplished
by the Institute of Behavioral Genetics, University of Colorado, Boulder [14–21].
The development of this patented GARS test involved the selection of ten reward
candidate genes that reflected a hypodopaminergic trait, including the dopamine receptors
(DRD1, 2, 3, 4); Dopamine Transporter (DAT1); serotonin transporter, COMT, MAO, GABA,
Mu opiate receptor, Single Nucleotide Polymorphisms (SNPs), and point mutations. The
genes determined to negatively influence the net release of dopamine at the brain reward
site were chosen from thousands of association studies providing clear evidence of specific
risk for all addictions.
The idea of “dopamine homeostasis” stems from the basic understanding of the importance of having a “normal” balance of not only dopamine but many well-characterized
neurotransmitters and even metabolic systems. To that end, further research is necessary to
understand the normative interface between hedonostatic and homeostatic mechanisms
and how their collapse is manifested in the mounting allostatic load and eventual addiction.
One additional thought worthwhile to consider herein is an ensuing field of addiction
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diabetology that could propel a unique multi-disciplinary collaboration unrestricted by
unnecessary boundaries separating addiction medicine and psychiatry from diabetology
and its related disciplines (e.g., dietology, primary care, nephrology, and ophthalmology), thus contributing to a greater depth and sophistication of clinical formulations and
therapeutic interventions.
This article aimed to provide the field with statistical validation of a number of
select reward-based genes and associated polymorphisms that primarily induce reduced
dopamine function in the meso-limbic brain reward circuitry. While the genetics proposed
herein are based on AUD cases and controls, we encourage further work to confirm this
and other known “reward processing dysregulation” as an expanded phenotype.
2. Materials and Methods
2.1. Literature Search and Inclusion of Eligible Studies
Studies investigating the association of each polymorphism with AUD or AUD-related
conditions were provided for a meta-analysis. They were published from 1990 to 2021.
Abstracts of studies were then examined to see whether these studies analyzed the association between the polymorphism of each candidate gene and AUD and/or AUD-related
conditions. The following criteria were necessary to be included in the review: (I) a peerreviewed publication; (II) a case–control design; (III) independent from the others (i.e.,
duplications were discarded, and studies with previously published data were excluded);
and (IV) sufficient information to compute an odds ratio (OR) and/or likelihood ratios (LR)
along with 95% confidence intervals (CI). If two studies contained overlapping samples,
the study with the larger sample size was kept for this meta-analysis.
2.2. Statistical Analysis
We first incorporated all the data from the selected studies to implement an overall
analysis and then conducted stratified analyses. All these analyses were two-sided by
default and were performed with the statistical programming language R. For this analysis,
the Hardy–Weinberg equilibrium of each polymorphism in cases and controls was assessed.
If available, the Pearson’s χ2 test or Fisher’s exact test was used for comparing gender,
genotype, and allele distribution. The age difference was evaluated with the Pearson’s
χ2 test and the Wilcoxon rank-sum test. To assess the association of each polymorphism
with AUD and AUD-related conditions, the summary OR and their 95% CI were estimated
for individual studies using the Pearson’s χ2 test if the contingency tables were available.
Considering between-study heterogeneities caused by different genders, ethnicities, nationalities, diagnostic criteria, and so on, both fixed-effects and random-effects models
were applied. For the fixed-effects analyses (i.e., the Mantel–Haenszel method), the effect
size of each individual study was integrated using inverse variance methods to generate a
pooled OR and 95% CI, assuming that the genotype effect is constant across studies and
the detected variation is attributable to random variation; see Laird and Mosteller [22]. For
the random-effects model, the effect sizes of individual studies were pooled, assuming
that the heterogeneity among studies is attributable to both between- and within-study
variations; see DerSimonian and Laird [23]. When compared to the fixed-effects model,
the random-effects model is more conservative and produces a broad CI. Thus, when no
significant heterogeneity is suspected among studies, the fixed-effects model tends to be
more appropriate. Otherwise, the random-effects model is recommended. The significance
of the pooled OR was ascertained using the standard Z-test (a 5% level of significance
was adopted for all the analyses). The Bonferroni correction was applied if multiple comparisons had to be performed. Repetition of the meta-analysis was conducted to run a
sensitivity analysis, with one study being omitted at a time, and no significant impact was
reported. Furthermore, based on the values of pre-test odds = pre-test risk/(1-pre-test risk),
the post-test odds were calculated as a product of OR and pre-test odds. Then, the post-test
risk was estimated by the value of post-test odds divided by 1 + post-test odds. For the
purpose of this analysis, the pre-test risk was assumed to be 8%.
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Cochran’s Q and I2 tests were employed to evaluate the potential heterogeneity among
various studies. The Cochran’s Q test was calculated as the weighted sum of squared differences between individual study effects and the pooled effect across studies, weighting the
contribution of each study by its inverse variance. The Q statistic follows a χ2 distribution
with n − 1 degrees of freedom (df), where n is the number of studies. The magnitude of
I2 = 1 − df/Q then describes the proportion of variation across studies caused by heterogeneity rather than by chance; see Higgins and Thompson [24]. Evidence of heterogeneity
between studies is indicated if I2 < 0.4. The method introduced by Hedges and Pigott [25,26] was used to approximate the statistical power of the meta-analysis. The funnel
plot test of Begg and Berlin [27] and the regression test of Egger et al. [28] were performed
to assess potential publication bias (see Galbraith [29]). The funnel plot utilizes a linear
regression approach to measure the funnel asymmetry on the natural logarithm of the
OR. The deviation of each study larger than the funnel-shaped distribution is predisposed
to be more prominently asymmetric, indicating a possibility of publication bias. If the
evidence of publication bias was noted, the trim and fill method of Duval and Tweedie [30]
was attempted to adjust the meta-analysis results by imputing data from presumed missing studies. The total number of patients used in this analysis was 74,566 case–control
subjects (Table 1).
3. Results
Table 2 summarizes the results of the statistical analyses, displaying the odds ratios
(OR), 95% confidence intervals (CI) for OR, and a post-risk estimated population alcoholism
prevalence of 8%. The dopamine receptor (DR) D1, DRD2, DRD3, DRD4, DAT1, COMT,
OPRM1, and 5HTT all showed substantial risk favoring cases of AUD when compared to
non-AUD controls using only the OR derived from this meta-analysis. However, because
of insufficient sample sizes, similar significance was not obtained for GABRB3 and MAOA.
The 95% CI supports this significant observation for OR except for GABRB3 and MAOA.
Once again, this might be due to smaller sample sizes. Moreover, except for DRD1, COMT,
GABRB3, and MAOA, the post-test risk was estimated at 8%. The pre-test risks all showed
a positive gain, allowing for predictability of AUD-related conditions based on the polymorphism. However, we did find a positive gain with DRD2 (0.12), DRD3 (0.20), DRD4
(0.10), DAT1 (0.10), and 5HTTLPR (0.10). With additional samples, this could be overcome.
Table 2. Odds ratios and likelihood ratios of polymorphisms under consideration.
Gene/Polymorphism

OR

95% CI
for OR

Post Risk

Dopamine D1 Receptor (DRD1): rs4532—risk allele G *

1.77

(1.01, 3.10)

-

Dopamine D2 Receptor (DRD2): rs1800497—risk allele A1

1.45

(1.15, 1.90)

0.12

Dopamine D3 Receptor (DRD3): rs6280—risk allele C (Ser9Gly)

3.37

(1.54, 7.40)

0.20

Dopamine D4 Receptor (DRD4): rs1800955—risk allele C (48bp repeat VNTR)

1.56

(1.04, 2.36)

0.10

Dopamine Transporter Receptor (DAT1): SLC6A3 30 -UTR—risk allele A9 (40bp
repeat VNTR)

1.18

(1.00, 1.45)

0.10

Catechol-O-Methyltransferase (COMT): rs4680—risk allele G (Val158Met)

1.43

(0.98, 2.10)

0.083

µ-Opioid Receptor (OPRM1): rs1799971—risk allele G (A118G)

1.47

(1.00, 2.18)

0.13

γ-Aminobutyric Acid (GABA) A Receptor, -3 Subunit (GABRB3): CA
repeat—risk allele 181

0.33

(0.14, 0.79)

0.06

Monoamine Oxidase A (MAO-A): 30 30bp VNTR-risk allele 4R DNRP

0.62

(0.15, 2.63)

0.05

Serotonin Transporter Receptor (5HTT) Linked Promoter Region (5HTTLPR) in
SLC6A4: rs25531—risk allele S0

1.23

(1.07, 1.40)

0.10

* Not enough data. It is noteworthy to point out that for each gene polymorphism, the number of cases and
controls has been indicated in Table 1.
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4. Discussion
We are not able to identify the OR for DRD1 currently. Given this, we will continue
to obtain additional case–control studies for each allele in the GARS that will allow for
the obtaining of OR statistics. It is anticipated that since we are close to having the proof
for each allele showing risk for AUD over controls (albeit not RDS free as it should be),
the incorporation of a new additional cohort of peer-reviewed and published works in the
literature should enable a more robust finding.
In some cases, the risk estimates for one copy of each variant (not all due to the
phenomena of heterosis) may be higher than ever for people with two copies of one variant.
However, because a patient with either one or two copies is managed similarly in a clinical
setting, the test report provided to the user will have the same interpretation as the test
report for both genotypes. While some more work needs to be accomplished, it is important
to highlight that at this stage, based on dichotomization of the GARS clinical data, any
combination of these gene-associated alleles that reaches the level ≤ 4 loads onto the risk
for drugs and gene-associated alleles that reaches the level ≤ 7 loads onto the risk for
AUD [31]. Once this work is accomplished, it should provide unequivocal evidence for the
validity of the selected risk gene-associated alleles. Although we claim that the selection of
these candidate genes reflects dopamine dysregulation in the realm of hypodopaminergia,
it is imperative to understand that the end function of dopamine at postsynaptic sites in
the mesolimbic system is the net result of at least seven neurotransmitter system iterations.
Dopamine is not alone and should not be considered in isolation.
With the advent of GWAS, there has been an explosion of very large studies related
to the genetic polymorphic antecedents of AUD. While others have found evidence for
a number of novel clusters of many genes, mostly second messengers, along with the
requirement for convergence of these genes to candidates, our approach focuses on finite
neurotransmitter pathways. We agree that future GWAS studies seem tantamount to
unlocking additional candidates for AUD risk, but we believe the present approach has
current hieratic value, requiring independent confirmation. While GWAS studies utilize
very large sample sizes and many SNPs, we are not convinced that controls utilized in
this sophisticated research reflect RDS-free symptomatology, which may prevent true
associations between disease and the controls (disease-ridden).
5. Study Limitations
Due to differences among studies (e.g., gender, age, family history, ethnicities, nationalities, comorbidities, the severity of AUD conditions, or unscreened controls), considerable
heterogeneity was observed, potentially resulting in publication bias (e.g., asymmetric
funnel plots) and/or increased false-positive rates (e.g., Type-I error rates). Not all studies
included in this analysis provided information regarding the aforementioned variables.
Many of the studies did not provide such information to allow us to exclude or include
patients with comorbid disorders in the reported samples; this makes it difficult to assess
the effect of the above covariates inducing heterogeneity among studies. Even though the
variables such as publication year, study populations, and diagnostic criteria did not seem
to be potential sources of heterogeneity, other possible sources of heterogeneity, such as the
onset and duration of alcohol addiction and other comorbid conditions or complications,
could not be assessed in this meta-analysis. AUD is a complex addictive disorder with
multifactorial pathogenesis and is often comorbid with other substance abuse or neuropsychiatric disorders, which likely share common genetic risk factors in the dopaminergic
reward system. The potential interaction of candidate genes with others may also lead to
heterogeneity among studies. The gene-by-gene or SNP-by-SNP interaction could not be
examined due to insufficient studies on other variants that significantly contribute to the
vulnerability of complex addictive phenotypes.
Furthermore, in this meta-analysis, only case–control studies were considered, which
are more susceptible to sampling bias resulting from the potential differences between alcoholics and control groups when compared to family-based studies; see Gamma et al. [32].
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The inter-rater reliability for selecting reported studies was not assessed, which might
lead to some biases. Additionally, the control groups in most of the studies included in
this review were not individuals randomly selected from the general population where
cases were selected, contributing to the potential bias in the study results. Selection bias
could also have occurred because the majority of the studies were published in English
only. An improved meta-analysis should be conducted using more sophisticated analysis methods for controlling between-study heterogeneity and publication bias, as well as
RDS-free controls.
Our work has been based on a number of candidate gene methods, which were first
initiated by the work of Blum and Noble in 1990 [33] as the first confirmed candidate
gene to be associated with alcoholism, as well as several other classic candidate gene
association studies in terms of accepted methodology [34–37]. While we are cognizant
of the pitfalls related to the candidate gene approach, including ancestry, we believe
the candidate approach currently has a clinically relevant outcome and heuristic value.
Certainly, the psychiatric genetic field is moving to GWAS instead of candidate gene
research, but convergence to candidate genes is required to make real sense of the enormity
of the data. One example of this type of GWAS analysis included a proxy-phenotype
meta-analysis of Problematic Alcohol Use (PAU), which combined AUD and problematic
drinking in 435,563 individuals of European ancestry [38]. They identified 29 independent
risk variants, 19 of them novel. PAU was genetically correlated with 138 phenotypes,
including substance use and psychiatric traits. Phenome-wide polygenic risk score analysis
in an independent biobank sample (BioVU, N = 67,589) confirmed the genetic correlations
between PAU and substance use and psychiatric disorders.
Moreover, a GWAS study involving a sample size of 1.2 million individuals involving both tobacco and alcoholism identified 566 polymorphisms in 406 loci associated
with various stages of tobacco use (heaviness, cessation, initiation) and alcohol use, with
150 loci providing evidence of a pleiotropic association [39]. However, when convergence
was applied, the authors identified several genes involved in dopaminergic, nicotinic,
and glutamatergic neurotransmission as well as other systems. Our concern related to
these GWAS studies and our subsequent evaluation is that the controls, for the most part,
that are utilized have not been adequately screened to eliminate all reward deficiency
symptomatology and associated disorders (i.e., gambling, hoarding, obesity, ADHD, etc.).
Hundreds of published studies about dopamine and its role in addictive and compulsive behaviors were reviewed in search of a reliable gene-based diagnostic test to identify
heritable risk factors for RDS. Our goal was to illustrate the process used to select the risk
alleles of reward genes for the GARS test and to address the limitations caused by inconsistent
results in many case–control behavioral association studies. Limitations are perhaps due to
the failure of investigators to adequately screen controls for drugs, AUD, and RDS behaviors,
including nicotine dependence, obesity, pathological gambling, and internet gaming addiction.
One example of accomplishing RDS-free controls is derived from Blum et al. [40], which
revealed the prevalence of the DRD2 A1 allele in unscreened controls (33.3%) compared to
“Super-Controls” (highly screened RDS controls (3.3%) in proband and family). Therefore, to
provide the best possible statistical analysis, any RDS-related behaviors must be eliminated
from the control group to avoid comparing the phenotype to disease-ridden controls.
In conclusion, unlike one gene-one disease (OGOD), RDS is polygenetic and complex.
Even though the genes evaluated are not the only ones associated with AUD, we focused
on these genes and the related polymorphisms because the available GARS test only
assesses genes chosen based on hypodopaminergia. Therefore, other genes such as alcohol
metabolism genes (e.g., alcohol dehydrogenase) combined with GARS may provide an
even stronger association in terms of risk. Certainly, utilizing genetic risk assessment in
any form will help identify early on the future risk, now termed “preaddiction” [41], which
is only one part of the equation to help attenuate future AUD or other RDS behaviors.
Early identification is indeed important in terms of prophylaxis, especially in our youth, as
evidenced by common brain mapping of addiction [42].
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Future Perspective
From 1999–2019, nearly 500,000 people have died from an opioid overdose, involving
any opioid, including prescription and illicit opioids [43]. While we are encouraging the
short-term utilization of opioid substitution treatment (OST), which may be useful for OST
in the short-term, to reduce harm, it is important to continue the quest for therapeutically
superior options. The goal for the future is to find a much better option.
To that end, we suggest one important way to help reduce overdose rates would be
OST incorporated into preventive and therapeutic strategies of metabolic assessments in
conjunction with established genetic risk assessment testing, such as the Genetic Addiction Risk Severity (GARS) complemented by, in combination with RDS, Questionnaire
RDSQ29 [44], or any other viable genetic assessment tool, to provide the potential early
identification of a newly identified concept, what has been now termed “Preaddiction”,
similar to “Prediabetes”, and assist in categorizing people with a high vs. low likelihood
of risk for glucoregulatory abnormalities, RDS and its associated bioinformatics (all addictions), which would contribute to a lesser likelihood of risk prior to deciding on the
prescribing of long-term powerful OST. Additionally, in the future, based on required
research, consideration must be given to the “Standard of Care”, which may be adjusted as
the putative induction of “homeo-dopamine hedonoomeostasis” is gaining further support in clinical and basic research, utilizing a number of pathophysiology-driven proven
modalities, including repetitive Transcranial Magnetic Stimulation (TMS), DBS (Deep Brain
Stimulation), and pro-dopamine regulation (e.g., KB220), as well as other viable solutions.
6. Conclusions
In summary, the results of the statistical analyses displayed the OR, 95% CI for OR, and a
post-risk estimated population alcoholism prevalence of 8%. Using only the OR derived from
this meta-analysis of 74,566 case–control subjects, DRD2, DRD3, DRD4, DAT1, COMT, OPRM1,
and 5HTT all showed significant risk favoring cases of AUD compared to non-AUD controls.
While the DRD1 gene did show a significant OR, the small sample size prevented us from
capturing the post-risk for 8% of the population. Figure 2 represents a schematic of our model.

Figure 2. Schematic of statistical validation of risk alleles in genetic addiction risk severity (GARS)
test: Early identification of risk for Alcohol Use Disorder (AUD) in 74,566 case-control subjects.
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